As we've shared previously, in our recent Phase 1/2 trial, which included patients who had two or more surgeries in the prior year, 81% saw a reduction in surgical interventions as compared to the year prior to treatment. Patients and advocates have expressed time and again that a reduction in even one surgery would have a profound impact. Moving on to VGX-3100. As announced in our press release, Inovio will cease further development of VGX3100 as a potential treatment for cervical HSIL in the U.S. This dec ...